Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study

医学 内科学 鼻咽癌 肿瘤科 危险系数 放化疗 诱导化疗 比例危险模型 单变量分析 多元分析 化疗 放射治疗 置信区间
作者
Xiaoli Mu,Hongyan Liu,Juan Wu,Shi Chen,Xingchen Peng,Jingjing Wang,Zhigong Wei,Ling He,Jiyan Liu,Zejun Lu,Yonglin Su
出处
期刊:Aging [Impact Journals LLC]
卷期号:14 (16): 6727-6739 被引量:8
标识
DOI:10.18632/aging.204246
摘要

BACKGROUND: Currently available evidence favors the combination of chemotherapy with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC). However, the optimal timing for additional chemotherapy is unclear. This study was conducted to compare the efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus concurrent chemoradiotherapy plus adjuvant chemotherapy (CCRT+AC). METHODS: Two medical centers in China enrolled patients with LANPC (stage III-IVB) between January 2009 and May 2020. Through the use of propensity score matching (PSM), baseline characteristics were balanced. The primary endpoint was overall survival (OS), which was evaluated by the Kaplan-Meier method and log-rank test. Potential independent prognostic factors were identified using univariate and multivariate Cox proportional hazard analyses. Based on the chi-squared test, we compared the adverse events associated with treatment between the groups. RESULTS: After the implementation of PSM, 159 patients treated with IC+CCRT and 72 patients treated with CCRT+AC were eventually enrolled in this study. There was no significant difference between patients treated with IC+CCRT and CCRT+AC in terms of 3-year OS (94.7% versus 90.9%, p=0.816), progression-free survival (PFS) (91.2% versus 83.1%, p=0.588), locoregional recurrence-free survival (LRFS) (92.5% versus 81.8%, p=0.478), or distant metastasis-free survival (DMFS) (93.4% versus 88.2%, p=0.783). There was no prognostic significance of the treatment for OS, PFS, LRFS, or DMFS (all p > 0.05) in the univariate and multivariate analyses. Patients treated with CCRT+AC had a higher incidence of grade 3 to 4 leucopenia (p=0.001) and neutropenia (p=0.001) than those treated with IC+CCRT. CONCLUSIONS: IC plus CCRT achieved comparable survival outcomes to CCRT plus AC and had a lower incidence of toxicity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Acklesism发布了新的文献求助10
刚刚
1秒前
动听沧海发布了新的文献求助10
1秒前
搜集达人的应助被礼礼采纳,获得10
1秒前
pluto的应助被123采纳,获得10
2秒前
2秒前
3秒前
3秒前
活泼的尔柳完成签到,获得积分10
3秒前
4秒前
4秒前
4秒前
rs10完成签到,获得积分10
4秒前
简单无极完成签到,获得积分10
7秒前
JHR发布了新的文献求助10
7秒前
深情安青的应助被入司采纳,获得30
7秒前
zwy发布了新的文献求助10
9秒前
852的应助被Creed采纳,获得10
9秒前
研磨7完成签到,获得积分10
10秒前
Lucas的应助被单纯的石头采纳,获得10
10秒前
英姑的应助被论文高手采纳,获得10
11秒前
11秒前
深情安青的应助被风之子采纳,获得10
11秒前
null的应助被钱念波采纳,获得10
11秒前
11秒前
娜比小新完成签到 ,获得积分10
12秒前
12秒前
CipherSage的应助被SUPEROUSI采纳,获得10
12秒前
14秒前
14秒前
Ashen_完成签到,获得积分10
15秒前
bkagyin的应助被EmocrazyT采纳,获得10
15秒前
15秒前
Tanyang发布了新的文献求助20
16秒前
渢薃完成签到,获得积分10
17秒前
流年发布了新的文献求助10
18秒前
18秒前
18秒前
123456完成签到,获得积分20
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition 800
Sustainable Engineered Micro/Nanofibers and Hybrid Nanocomposites for Environmental Remediation 400
Ecotourism 400
Liquidus diagram and viscosity estimation in pseudo-binary system Li2B6O10–LiF 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8075007
求助须知:如何正确求助?哪些是违规求助? 9493543
关于积分的说明 21374969
捐赠科研通 7642507
什么是DOI,文献DOI怎么找? 3399678
关于科研通互助平台的介绍 2529365
邀请新用户注册赠送积分活动 2438303